What does real-world evidence tell us about therapies targeting the CGRP pathway in migraine prevention?
Four monoclonal antibodies (mAbs) targeting the calcitonin gene related peptide (CGRP) pathway are currently approved by the US Food and Drug Administration and European Medicines Agency for the preventive therapy of migraine.1–3 These agents target either the CGRP ligand or its receptor, and each has demonstrated efficacy and safety in short- and long-term clinical trials.
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.Log In
Not registered yet? Register now